3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Ovarian Neoplasms
10
Fallopian Tube Neoplasms
10
Breast Neoplasms
7
Endometrial Neoplasms
5
Neoplasms
4
Triple Negative Breast Neoplasms
3
Prostatic Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Urinary Bladder Neoplasms
2
Pheochromocytoma
2
Paraganglioma
2
Osteosarcoma
2
Neuroendocrine Tumors
2
Neuroblastoma
2
Metastatic Castration-resistant Prostate Cancer
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Glioma
2
Glioblastoma
2
Ependymoma
2
Cholangiocarcinoma
2
Xanthogranuloma, Juvenile
1
Wilms Tumor
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Interventions
Cisplatin
12
Gemcitabine
9
Specimen Handling
6
Radiotherapy, Intensity-Modulated
6
Magnetic Resonance Spectroscopy
6
Drug Therapy
5
toripalimab
4
Platinum
4
Nivolumab
4
Capecitabine
4
1,2-diaminocyclohexaneplatinum II citrate
4
spartalizumab
3
Radiotherapy
3
Immune Checkpoint Inhibitors
3
sintilimab
2
Ipilimumab
2
Immunoglobulin G
2
Docetaxel
2
Disulfides
2
Carboplatin
2
CTLA-4 Antigen
2
Biopsy
2
tislelizumab
1
relatlimab
1
pembrolizumab
1
olaparib
1
fluciclovine F-18
1
dehydroftorafur
1
cemiplimab
1
camrelizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Nasopharyngeal Carcinoma
×
olaparib
×
30 days
×
Clear all
NCT04825990
2026-06-01
POINT
Gruppo Oncologico del Nord-Ovest
Phase 2
Active not recruiting
30 enrolled